These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 23089710)

  • 1. Measuring Rivaroxaban in a clinical laboratory setting, using common coagulation assays, Xa inhibition and thrombin generation.
    Molenaar PJ; Dinkelaar J; Leyte A
    Clin Chem Lab Med; 2012 Oct; 50(10):1799-807. PubMed ID: 23089710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rivaroxaban demonstrates in vitro anticoagulant effects in canine plasma.
    Conversy B; Blais MC; Dunn M; Gara-Boivin C; Carioto L; del Castillo JR
    Vet J; 2013 Nov; 198(2):437-43. PubMed ID: 24053991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels.
    Francart SJ; Hawes EM; Deal AM; Adcock DM; Gosselin R; Jeanneret C; Friedman KD; Moll S
    Thromb Haemost; 2014 Jun; 111(6):1133-40. PubMed ID: 24401946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor.
    Samama MM; Martinoli JL; LeFlem L; Guinet C; Plu-Bureau G; Depasse F; Perzborn E
    Thromb Haemost; 2010 Apr; 103(4):815-25. PubMed ID: 20135059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls.
    Samama MM; Contant G; Spiro TE; Perzborn E; Guinet C; Gourmelin Y; Le Flem L; Rohde G; Martinoli JL;
    Thromb Haemost; 2012 Feb; 107(2):379-87. PubMed ID: 22187012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The in-vitro anticoagulant effect of rivaroxaban in neonates.
    Attard C; Monagle P; Kubitza D; Ignjatovic V
    Blood Coagul Fibrinolysis; 2014 Apr; 25(3):237-40. PubMed ID: 24418940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assays for measuring rivaroxaban: their suitability and limitations.
    Lindhoff-Last E; Samama MM; Ortel TL; Weitz JI; Spiro TE
    Ther Drug Monit; 2010 Dec; 32(6):673-9. PubMed ID: 20844464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of anti-Xa and dilute Russell viper venom time assays in quantifying drug levels in patients on therapeutic doses of rivaroxaban.
    Gosselin RC; Adcock Funk DM; Taylor JM; Francart SJ; Hawes EM; Friedman KD; Moll S
    Arch Pathol Lab Med; 2014 Dec; 138(12):1680-4. PubMed ID: 25427046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro.
    Perzborn E; Heitmeier S; Laux V; Buchmüller A
    Thromb Res; 2014 Apr; 133(4):671-81. PubMed ID: 24529498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of rivaroxaban, in contrast to heparin, is similar in neonatal and adult plasma.
    Novak M; Schlagenhauf A; Bernhard H; Schweintzger S; Leschnik B; Muntean W
    Blood Coagul Fibrinolysis; 2011 Oct; 22(7):588-92. PubMed ID: 21799400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of methods to determine rivaroxaban anti-factor Xa activity.
    Rathbun S; Tafur A; Grant R; Esmon N; Mauer K; Marlar RA
    Thromb Res; 2015 Feb; 135(2):394-7. PubMed ID: 25476589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitory effect of apixaban compared with rivaroxaban and dabigatran on thrombin generation assay.
    Wong PC; White A; Luettgen J
    Hosp Pract (1995); 2013 Feb; 41(1):19-25. PubMed ID: 23466964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Point-of-care coagulation testing for assessment of the pharmacodynamic anticoagulant effect of direct oral anticoagulant.
    Mani H; Herth N; Kasper A; Wendt T; Schuettfort G; Weil Y; Pfeilschifter W; Linnemann B; Herrmann E; Lindhoff-Last E
    Ther Drug Monit; 2014 Oct; 36(5):624-31. PubMed ID: 24577124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-coagulation assessment with prothrombin time and anti-Xa assays in real-world patients on treatment with rivaroxaban.
    Königsbrügge O; Quehenberger P; Belik S; Weigel G; Seger C; Griesmacher A; Pabinger I; Ay C
    Ann Hematol; 2015 Sep; 94(9):1463-71. PubMed ID: 26025632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Laboratory assessment of novel oral anticoagulants: method suitability and variability between coagulation laboratories.
    Helin TA; Pakkanen A; Lassila R; Joutsi-Korhonen L
    Clin Chem; 2013 May; 59(5):807-14. PubMed ID: 23378569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays.
    Hillarp A; Baghaei F; Fagerberg Blixter I; Gustafsson KM; Stigendal L; Sten-Linder M; Strandberg K; Lindahl TL
    J Thromb Haemost; 2011 Jan; 9(1):133-9. PubMed ID: 20946166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rivaroxaban: Quantification by anti-FXa assay and influence on coagulation tests: a study in 9 Swiss laboratories.
    Asmis LM; Alberio L; Angelillo-Scherrer A; Korte W; Mendez A; Reber G; Seifert B; Stricker H; Tsakiris DA; Wuillemin WA
    Thromb Res; 2012 Apr; 129(4):492-8. PubMed ID: 21840043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rivaroxaban differentially influences ex vivo global coagulation assays based on the administration time.
    Mani H; Hesse C; Stratmann G; Lindhoff-Last E
    Thromb Haemost; 2011 Jul; 106(1):156-64. PubMed ID: 21655672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measurement of dabigatran and rivaroxaban in primary prevention of venous thromboembolism in 106 patients, who have undergone major orthopedic surgery: an observational study.
    Samama MM; Guinet C; Le Flem L; Ninin E; Debue JM
    J Thromb Thrombolysis; 2013 Feb; 35(2):140-6. PubMed ID: 23335022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays.
    Gosselin R; Grant RP; Adcock DM
    Int J Lab Hematol; 2016 Oct; 38(5):505-13. PubMed ID: 27265752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.